RxDoctor Payments Data

Meagen McCusker, MD

Dermatology · Enfield, CTNPI 1861651432

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $1,312,320 of the $1,818,460 with a category attached, or 72.2%. 50 manufacturers reported payments, led by AbbVie at 31.4% of the total. 2025 is the largest year on record at $519,573, 4.0 times the $129,195 reported in 2019. Among dermatology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,818,460in general payments, 2019–2025

Across 2,798 payments — averaging $649.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$570K
  • Sanofi$283K
  • Regeneron Healthcare Solutions, Inc.$259K
  • Amgen$182K
  • Pfizer$116K
  • Lilly USA, LLC$104K
  • plus $304K from 44 others

What the payments were for

  • Consulting fees$233,17413%
  • Speaking & faculty fees$1,312,32072%
  • Travel & lodging$206,56311%
  • Food & beverage$66,0284%
  • Education$3750%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,818,460 in reported general payments places this provider in the 95th percentile of 222 dermatology providers in Connecticut.

See all dermatology providers in Connecticut

Medicare billing

Part B allowed, 2024
$338,552
Medicare patients
631
Services billed
6,502

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib47$377,665
Dupixent PenDupilumab75$281,324
Cosentyx Unoready PenSecukinumab22$161,378
HumiraAdalimumab11$146,202
Dupixent SyringeDupilumab21$99,918
Cosentyx Sensoready (2 Pens)Secukinumab12$87,151
AdbryTralokinumab-Ldrm11$65,656
JubliaEfinaconazole13$11,330
Mycophenolate Mofetil16$7,777
Fluorouracil111$6,524
Doxycycline Monohydrate99$2,424
ValacyclovirValacyclovir Hcl72$2,342
Betamethasone Dipropionate53$2,159
Minoxidil90$1,999
Clobetasol Propionate45$1,911

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira$570,499$523,86758 claims
LEO Pharma Inc.Adbry$26,004$65,65611 claims
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$734$11,33013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 222 dermatology providers in Connecticut.

Other dermatology in Enfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →